Centre Hospitalier du Mans

Running trials

• Recruiting

  A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

  NCT07218146· Phase 3· Source

• Recruiting

  This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

  NCT07290803· Source

• Recruiting

  Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

  NCT07039110· Source

• Active, not recruiting

  Evaluation of the Efficacy of an Innovative Digital Therapeutic Medical Device, Lyv Endo, for the Management of Patients With Endometriosis

  NCT07175857· Source

• Recruiting

  Prediction of Peripheral Neuropathy With Functional Testing

  NCT06933108· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT06588478· Phase 2· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· Source

• Recruiting

  Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

  NCT06191263· Phase 2· Source

• Recruiting

  Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients

  NCT06067906· Source

• Active, not recruiting

  An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World

  NCT05669794· Source

• Active, not recruiting

  An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

  NCT05363319· Source

• Active, not recruiting

  Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

  NCT05222555· Phase 1/2· Source

• Recruiting

  Prediction of Chronic Kidney Disease Following Pre-eclampsia: Diagnosis and Early Care

  NCT05056701· Source

• Recruiting

  A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  NCT04988555· Phase 1/2· Source

• Active, not recruiting

  STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia

  NCT04963946· Phase 2· Source

• Recruiting

  Evaluation of Patient Satisfaction and Therapeutic Impact Regarding Joint Consultation Rheumatologist/Dermatologist

  NCT04800289· Source

• Recruiting

  Protecting Kidneys Through a Low Protein Diet: A Stepwise Multiple-Choice System Approach

  NCT03979534· Source

• Active, not recruiting

  Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

  NCT03734198· Phase 2· Source

• Active, not recruiting

  A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

  NCT03223961· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease3 recruiting
• Acute myeloid leukemia2 recruiting
• Lung cancer2 recruiting
• Psoriasis2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Obesity1 recruiting
• Psoriatic arthritis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

  NCT06505018· Source

• Terminated

  Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

  NCT06268574· Phase 2· Source

• Completed

  A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

  NCT05071664· Phase 2· Source

• Completed

  A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

  NCT04968912· Phase 2· Source

• Completed

  A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

  NCT04266795· Phase 2· Source

• Completed

  A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

  NCT04458831· Source

• Completed

  Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

  NCT04010968· Phase 2· Source

• Completed

  Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

  NCT03982394· Source

• Completed

  A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

  NCT03596866· Phase 3· Source

• Completed

  A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis

  NCT03818035· Phase 3· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Source

• Completed

  A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

  NCT03734016· Phase 3· Source

• Completed

  Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia

  NCT03415035· Source

• Completed

  Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

  NCT03268954· Phase 3· Source

• Completed

  A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

  NCT03104374· Phase 3· Source

• Completed

  Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

  NCT02784171· Phase 2/3· Source

• Terminated

  A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

  NCT02841540· Phase 1· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Source

Trial sites

• Centre Hospitalier du Mans10 trials
• Centre Hospitalier Du Mans - Cancérologie Médicale0 trials
• Centre Hospitalier du Mans /ID# 1637461 trial
• Centre Hospitalier du Mans /ID# 1694511 trial
• Centre Hospitalier du Mans /ID# 2059910 trials
• Centre Hospitalier du Mans /ID# 2151480 trials
• Centre Hospitalier du Mans /ID# 2257291 trial
• Centre Hospitalier du Mans /ID# 2505101 trial
• Centre Hospitalier du Mans /ID# 2605100 trials
• Centre Hospitalier du Mans /ID# 2618520 trials
• Centre Hospitalier Du Mans /ID# 2798991 trial
• Centre Hospitalier du Mans (Site 1002)0 trials
• Centre Hospitalier du Mans-Site Number: 25000041 trial
• Centre Hospitalier Le Mans20 trials
• Centre Hospitalier Le Mans /ID# 1597020 trials
• Centre Hospitalier Le Mans - Investigational Site Number : 25000151 trial
• Centre Hospitalier - Le Mans _ Service de Neurologie0 trials
• Centre Hospitalier Le Mans (Site 0406)0 trials
• Ch - Centre Hospitalier Du Mans0 trials